Rhinosinusitis is an inflammation of the paranasal sinuses and the nasal cavity lasting no longer than 4 weeks. It can range from acute viral rhinitis (the common cold) to acute bacterial rhinosinusitis. Fewer than 5 in 1,000 colds are followed by bacterial rhinosinusitis.
Like other countries in the world, Japan has witnessed a worrisome increase in the prevalence of chronic rhinosinusitis (CRS) over the last decade.
Researchers investigated the changes in olfactory bulb volume and structural connectivity of the brain in patients with olfactory dysfunction following mild SARS-CoV-2.
The oil washed ashore every day, globs of tarlike ooze blighting sugar-white sand beaches. Rodney Boblitt's job was to report it.
In a recent study published in the Respiratory Research journal, researchers in Hong Kong assessed the deterioration of asthma control in patients recovering from mild to moderate coronavirus disease 2019 (COVID-19).
In a new study posted to the medRxiv* preprint server, scientists in the United States assessed the extent of post-COVID-19 olfactory and gustatory dysfunction to gain deeper insights into the quality and severity of the symptoms over a year.
Researchers investigated whether using patient-preferred scents and a bimodal method of visual-olfactory training is more effective than unimodal olfactory training using scents assigned by physicians in treating patients experiencing anosmia after COVID-19.
Researchers debunk man flu based on a review of available evidence.
Alzheimer's disease (AD) is a type of dementia that affects memory, thinking and behavior. According to the Alzheimer's Association, an estimated 6.2 million Americans are living with this progressive neurologic disorder, and it is the sixth-leading cause of death in the U.S.
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.
Researchers determine the inhibition capacity of iota-carrageenan and xylitol in three different candidate preservative-free formulations.
SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is highly transmissible, with nasal passages being the target of original infection.
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
The millions of people who have chronic sinusitis deal not only with stuffy noses and headaches, they also commonly struggle to focus, and experience depression and other symptoms that implicate the brain's involvement in their illness.
News-Medical catches up with Professor Carl Philpott about the latest findings regarding COVID-19 and smell loss.
De'Broski Herbert has a philosophy that's guided his career researching helminths, or parasitic worms, and their interaction with their hosts' immune systems: "Follow the worm."
Researchers in the United States have demonstrated the antiviral effect of three candidate nasal spray formulations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).
Scientists at Johns Hopkins Medicine, experimenting with a small number of human cell samples, report that the "hook" of cells used by SARS-CoV-2 to latch onto and infect cells is up to 700 times more prevalent in the olfactory supporting cells lining the inside of the upper part of the nose than in the lining cells of the rest of the nose and windpipe that leads to the lungs.
Beneficial strains of bacteria residing in our guts, genital tracts, and skin have been shown to play a role in human health, and now, researchers publishing May 26 in the journal Cell Reports suggest that some of these "good" bacteria also have a niche in our noses.
Eosinophilic chronic rhinosinusitis is a type of airway disease involving nasal inflammation. Many studies have attempted to understand the molecular-based pathogenesis of recurrent ECRS; none have provided a clear explanation, until now.
Nasal saline and corticosteroid sprays are pretty standard treatment for individuals battling chronic rhinosinusitis.